Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
131.3 USD | +2.08% | +1.40% | +20.49% |
04:04pm | Merck to present new oncology data | CF |
May. 14 | US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine | RE |
MarketScreener Strategies
Merck and Company : Leader in oncology, modest valuation | October 29, 2019 at 11:04 am EDT |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- MarketScreener Strategies